Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash from Financing Activities (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Cash from Financing Activities for 6 consecutive years, with $934000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 16.75% to $934000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $220.6 million through Dec 2025, down 18.33% year-over-year, with the annual reading at $1.6 million for FY2025, 99.41% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $934000.0 at Relay Therapeutics, up from $17000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $384.0 million in Q4 2021, with the low at $17000.0 in Q3 2025.
  • Average Cash from Financing Activities over 5 years is $54.7 million, with a median of $1.8 million recorded in 2022.
  • The sharpest move saw Cash from Financing Activities surged 685635.71% in 2021, then tumbled 99.99% in 2025.
  • Over 5 years, Cash from Financing Activities stood at $384.0 million in 2021, then tumbled by 99.7% to $1.2 million in 2022, then surged by 1779.76% to $21.9 million in 2023, then crashed by 96.35% to $800000.0 in 2024, then increased by 16.75% to $934000.0 in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $934000.0, $17000.0, and $800000.0 for Q4 2025, Q3 2025, and Q4 2024 respectively.